Skip to content
NAD+ Picks
← Research
Evidence

Nicotinamide, niacinamide and niacin: what is actually different

Nicotinamide and niacinamide are two names for one molecule — the amide form of vitamin B3 and the direct building block of NAD⁺. Niacin is a different compound, and it is the one that makes you flush. Here is how all three relate, and the one trial with a hard outcome.

Rachel Kim6 min read
Four names on a shelf, one destinationnicotinamide = niacinamideone compound, two namesno flush at supplement dosesniacin (nicotinic acid)a different compoundthe one that causes the flushnicotinamide riboside · NMNnicotinamide with extra parts attachedNAD+the coenzymeEvery route ends in the same place. What differs is cost, tolerability and how much has been tested.

Nicotinamide and niacinamide are the same molecule. Two names, one compound — the amide form of vitamin B3, and the direct building block your cells use to make NAD⁺. Dermatology and cosmetics tend to write “niacinamide”; biochemistry and pharmacology tend to write “nicotinamide”. Nothing else is different.

Niacin is not the same molecule. Niacin — nicotinic acid — is the other common form of vitamin B3, and the difference is not cosmetic: at pharmacological doses niacin causes the flushing reaction, and nicotinamide does not. Both converge on NAD⁺ in the end.

Where nicotinamide sits relative to NAD⁺

Most of the NAD⁺ in your body is recycled rather than built from scratch, through a route called the salvage pathway. Enzymes that consume NAD⁺ — sirtuins and PARPs among them — release nicotinamide as a by-product, and the enzyme NAMPT converts that nicotinamide back to NMN, which is then converted to NAD⁺. Nicotinamide is the molecule going round the loop.

Which explains the naming on every supplement label in this category. Nicotinamide riboside is nicotinamide with a ribose sugar attached. Nicotinamide mononucleotide is nicotinamide riboside with a phosphate on top. They are the same core molecule entering the pathway at different points, which is the real subject of NMN versus NR — and it is why plain nicotinamide, which costs a fraction of either, is a legitimate question to put to anyone selling you the branded versions.

The one nicotinamide trial with a hard outcome

Most of the NAD⁺ literature stops at a blood level. Nicotinamide is the exception, and it is worth knowing about precisely because the endpoint is a real clinical event.

A phase 3, double-blind, randomized trial assigned 386 participants who had had at least two nonmelanoma skin cancers in the previous five years to 500 mg of nicotinamide twice daily or placebo for 12 months. At 12 months the rate of new nonmelanoma skin cancers was 23% lower in the nicotinamide group (95% CI 4 to 38, P = 0.02), with the number of actinic keratoses 13% lower at 12 months (P = 0.001). There were no notable between-group differences in adverse events — and no evidence of benefit after nicotinamide was stopped [1].

Read that carefully, because it is routinely stretched. It is a chemoprevention result in high-risk skin-cancer patients, not a finding about energy, aging or general wellness, and the benefit did not persist once the tablets stopped. It is nevertheless the strongest outcome evidence any form of vitamin B3 has, which tells you something about how thin the rest of the shelf is.

Niacinamide on your face versus nicotinamide in a capsule

Same compound, entirely different exposure. Topical niacinamide in a serum is formulated for the skin barrier; an oral nicotinamide tablet is a systemic dose. Evidence for one does not transfer to the other, and a product page that cites the skin-cancer trial to sell a face cream is borrowing credibility it has not earned.

The same caution applies in the other direction. Nicotinamide is not risk-free at arbitrary doses — the skin-cancer trial used 500 mg twice daily under supervision, in patients with a specific indication, for a defined period. Whether any dose is appropriate for you is a clinician’s call, and what is known about safety by format is the context to bring to that conversation.

Does nicotinamide raise NAD⁺ the way the branded precursors do?

It enters the same pathway, and the branded precursors have the published human pharmacology. An eight-week randomized, placebo-controlled trial of nicotinamide riboside at 100, 300 and 1,000 mg raised whole blood NAD⁺ by 22%, 51% and 142% within two weeks, with no reports of flushing and no significant difference in adverse events against placebo [2]. Equivalent dose-ranging data for plain nicotinamide marketed as an NAD⁺ booster is not what that literature is made of.

So the honest position is that nicotinamide is cheap, well characterized as a vitamin, and the molecule at the center of the whole pathway — and that the specific claim “this raises your NAD⁺ by X%” has been measured for NR and NMN rather than for it. If that biomarker is what you are buying, the products with the measurement behind them are on our supplement board.

And if a clinic is quoting the word “nicotinamide” at you while selling an infusion, note that those are different products with very different price tags — what IV NAD⁺ actually involves covers what that route does and does not buy you.

Frequently asked

Is nicotinamide the same as niacinamide?
Yes — two names for one compound, the amide form of vitamin B3. Dermatology and cosmetics usually write niacinamide; biochemistry and pharmacology usually write nicotinamide. There is no chemical difference between them.
Is nicotinamide the same as niacin?
No. Niacin is nicotinic acid, a different compound and the other common form of vitamin B3. The practical difference is the flushing reaction: niacin causes it at pharmacological doses and nicotinamide does not. Both are routes to NAD⁺ in the end.
How is nicotinamide related to NAD⁺?
It is the molecule at the center of the salvage pathway, the route that recycles most of your NAD⁺. Enzymes that consume NAD⁺ release nicotinamide, which NAMPT converts back to NMN and then to NAD⁺. Nicotinamide riboside is nicotinamide with a ribose attached, and NMN is that plus a phosphate.
What did the nicotinamide skin cancer trial find?
In a phase 3 trial of 386 people who had had at least two nonmelanoma skin cancers in the previous five years, 500 mg of nicotinamide twice daily for 12 months lowered the rate of new nonmelanoma skin cancers by 23% against placebo (95% CI 4 to 38, P = 0.02). The benefit did not persist after nicotinamide was stopped, and the result is about skin-cancer chemoprevention rather than aging or energy.
Should I just take cheap nicotinamide instead of NR or NMN?
It is a fair question to put to any seller, since all three enter the same pathway and nicotinamide costs far less. What NR and NMN have that plain nicotinamide marketed as an NAD⁺ booster does not is published dose-ranging data in humans — for example a 22%, 51% and 142% rise in whole blood NAD⁺ at 100, 300 and 1,000 mg of nicotinamide riboside. If the measured biomarker is what you are paying for, that is where it has been measured.

Sources

  1. [1] Chen AC, Martin AJ, Choy B, et al. (2015). A Phase 3 Randomized Trial of Nicotinamide for Skin-Cancer Chemoprevention New England Journal of Medicine. PMID 26488693
  2. [2] Conze D, Brenner C, Kruger CL. (Funding/affiliation: ChromaDex Spherix Consulting — the ingredient manufacturer) (2019). Safety and Metabolism of Long-term Administration of NIAGEN (Nicotinamide Riboside Chloride) in a Randomized, Double-Blind, Placebo-controlled Clinical Trial of Healthy Overweight Adults Scientific Reports. PMID 31278280

Where to get it

Best NAD⁺ injections

Every injection provider we can verify, with the price each one publishes and an honest read of what injectable NAD⁺ has been shown to do.

Compare providers →

More in Evidence